about
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and EnzalutamideProspective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging–Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy CohortPotential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial.The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited.Prostate cancer: multiparametric MR imaging for detection, localization, and staging.A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer.Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.Prostate cancer biomarker profiles in urinary sediments and exosomes.Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes.Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.Quality of life after prostate cancer treatments in patients comparable at baseline.Fear of cancer recurrence in prostate cancer survivors.Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer.PREDICT: model for prediction of survival in localized prostate cancer.Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI.Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy.CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.The length of positive surgical margins correlates with biochemical recurrence after radical prostatectomy.Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility.223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily Practice.Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.Fear of cancer recurrence: a significant concern among partners of prostate cancer survivors.Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases.Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.Novel use of Twitter to disseminate and evaluate adherence to clinical guidelines by the European Association of Urology.Difficulties in pain management using oxycodone and fentanyl in enzalutamide-treated patients with advanced prostate cancer.Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.Development and Validation of A Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Metastatic Castration-Resistant Prostate Cancer Patients.Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.[Multiparametric MRI for prostate cancer screening]Known susceptibility SNPs for sporadic prostate cancer show a similar association with “hereditary” prostate cancer
P50
Q28076820-F97474A8-FEF6-4BFF-8DFE-E41B953A59CDQ29037865-B09B6B35-7D4F-49BE-A3C0-D88338B2B28EQ34536729-8CBA4465-211B-4B0A-B7C3-A1C50882AD20Q37321426-FC110D15-AA54-431B-83ED-6BE7898DC0E6Q37349051-4388D26C-14E8-4C72-A0FF-1868D5D599CBQ37935483-C40FE299-8413-4E33-854A-B700615E023FQ38602540-FF668BF2-9C24-460A-BC44-5220791DE629Q38786630-854AA3A4-511E-4831-8541-2DC2B58EA4FDQ38846463-1D37BABC-889B-4A84-903B-96D154F13977Q39470254-BFD1837B-1098-4EB3-BF2F-9DEB773BDA53Q40111647-29738913-836F-424D-9AEB-0F18AF74312FQ40148908-C6EAC892-0A88-41E4-8B8F-3D2F6EB5B71DQ40335169-3C351947-FB62-4628-81BC-7A1015EBECFFQ40368993-88C49D44-5BED-4C37-9646-B368A65234BEQ40844364-E5587B7F-1E1B-47F3-BEC2-D4F60FFE4207Q40875743-B1E39072-3A2C-4E1E-A04B-19275513A247Q41195275-A97E72D7-7A97-43AA-9509-2AD7DA5DCD12Q41288229-D08AEDC6-E292-40FE-BC04-8254FEA40462Q41339007-67FDEA14-E6F2-4AD1-9D66-6897EDC7E36EQ43094574-68DAF72E-AF42-4B62-8186-154B2B751C7BQ43197140-7696C9CF-A398-48DD-9DE2-28534E50CDC2Q43433131-5398CD89-5D55-4A18-B5B8-625C0136E3B0Q44105572-0FE6E8CF-8834-4F10-AAB4-5B5C26F35205Q45032576-C6C4C0E4-3C21-402F-A7E7-840901760A72Q46233607-878F7883-E9F1-4994-8F09-8FF0BE6C305EQ46644825-C6414C44-9860-4274-8A7E-72F6CCDBBA87Q47427926-0B3D1B78-C250-42B2-96AF-11C33D053288Q47563953-9EF8042D-5CF1-42E1-BAF5-78E4F615EF54Q47772553-8124CD9B-92BF-4178-9B5C-ADC2229271B6Q47904198-443D7B9E-7314-45C8-B411-91040763C1C3Q48021275-5CCA02F1-A07B-488B-A7A7-6C27D033E6D3Q48109856-DB0D5EBF-6EC5-428A-9F3F-374FFCFEFE34Q48267050-A7C5C174-D883-49AD-983F-AA992895DA66Q49632584-81B0B85B-001D-425F-BCA8-3674467F60D6Q50054869-C5912E71-4D3E-417F-95DF-D457FCA4EC36Q50099663-DADF0E53-B6F2-4A8D-A783-465033D2BBB9Q50117720-0B3CBDAA-2913-44F5-9A22-027D7229D9D9Q54379716-43ADA65F-2DBC-4814-86D6-53B8D70C7056Q57142989-86233C9C-E6E0-4421-90D7-2B39D4041983Q57307160-75B3998B-5053-42E7-AF20-276E4B26939A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Inge M. Van Oort
@en
Inge M. Van Oort
@nl
type
label
Inge M. Van Oort
@en
Inge M. Van Oort
@nl
altLabel
van Oort IM
@en
prefLabel
Inge M. Van Oort
@en
Inge M. Van Oort
@nl
P31
P496
0000-0002-8002-1869